Kiran Mahajan, MSc, PhD
Associate Professor of Surgery
Chief, Section of Surgical Therapeutics
Division of Surgical Sciences
Division of Urologic Surgery
- Phone: 314-273-7728
Specialties
- Prostate cancer
- Biomarkers
- Epigenetics
- Drug discovery
- Therapeutics
Contact the Mahajan Lab: 314-273-7728
Meet Dr. Mahajan
Dr. Kiran Mahajan is a scientist specializing in urologic research for the development of therapeutics.
She has expertise in the processing of mechanism-based development of biomarkers and therapeutics for clinically significant prostate cancers.
Dr. Mahajan earned her doctorate in biotechnology from the Indian Institute of Science. She completed a cancer research fellowship at Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill.
My laboratory studies the pathogenic role of epigenetic regulators in prostate cancer development and progression, with a focus on the mechanisms by which these factors co-operate with transcription factors to drive tumor heterogeneity and resistance to various standard of care therapies such as radiotherapy, anti-androgen therapy and immune therapy.
Dr. Mahajan
Degrees
Master of Science in Biotechnology Madurai Kamaraj University, Madurai, India 1991
Doctorate in Biotechnology Indian Institute of Science, Bangalore, India 1998
Fellowship
Cancer Research Fellowship Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 2004
Research interests
Pathogenic role of epigenetic regulators
Prostate cancer development and progression
Transcription factors to drive tumor heterogeneity
Tumor resistance to standard care therapies
Radiotherapy
Anti-androgen therapy
Immune therapy
Dr. Kiran Mahajan in the news
- New strategy against treatment-resistant prostate cancer identified
- Siteman investment program awards $1.89 million in cancer research grants
Professional Memberships
American Association for Cancer Research
American Urological Association
Awards and Honors
- 2021-2024 DOD PCRP Translational Science Award
- 2020 Nanostring miRNA Grant Winner St. Louis region
- 2019-2020 Phi Beta Psi Sorority Award
- 2019-2020 Leadership in Entrepreneurial Acceleration Program (LEAP) Challenge Award
- 2017 Co-Investigator, Movember Foundation-PCF Challenge Award, Basic Science Top Publication Award for 2017, Moffitt Cancer Center
- 2015-2016 Department of Defense Exploratory Hypothesis Awards, Department of Defense, USA
- 2014-2015 Department of Defense Exploratory Hypothesis Award, Department of Defense, USA
- 2012-2013 Department of Defense Exploratory Hypothesis Award, Department of Defense, USA
- 2001-2004 Ruth Kirschstein National Research Service Award, National Institutes of Health, USA
- 1998 Professor Giri Memorial Medal for the Best Doctoral Dissertation by the Department of Biochemistry, Indian Institute of Science, Bangalore
- 1991-1996 University Graduate Scholarship by the Council of Scientific and Industrial Research (CSIR) India
- November 1996 Best Poster at The 64th Annual Meeting of the Society of Biological Chemists (India), Indian Institute of Science, Bangalore, India
- 1989-1991 Masters Scholarship, Department of Biotechnology, Govt. of India
Innovations
Title: Inhibitors of ACK1/TNK2 Tyrosine Kinase
Chinese Patent No. ZL 201480054401.3
Filing Date: August 6, 2014
Issue Date: Jan 8, 2020
Title: AKT Tyrosine 176 Phosphorylation as Cancer Biomarker US Patent No. 8,557,516
Filed Date: February 8, 2010
Issue Date: October 15, 2013
pTyr176-AKT antibody (Hybridomas) is patented by Moffitt and has been licensed for commercial Cancer diagnostic kit
Title: Antibodies specific for phosphorylated histones and uses thereof
Patent No. 9,594,084
Filed Date: July 2, 2014
Issue Date: March 14, 2017
European Patent No. EP 2 800 819 B
Issue Date: April 4, 2018
Published in the European Patent Bulletin No. 18/14
Phospho- Histone antibodies have also been licensed for commercialization
Title: Methods for treatment of disorders related to phosphorylation of histones Application # 14/860,405
Filing Date: September 23, 2014
Title: Inhibitors of ACK1/TNK2 Tyrosine Kinase
US Patent No 9,850,216
14833894.0 (European); 201480054401.3 (China); 201637004441 (India)
Filing Date: August 6, 2014
Issue Date: December 26, 2017
This technology has been licensed
Title: Inhibitors of ACK1/TNK2 Tyrosine Kinase
Application # 15/748,214; 62/200,084; 62/299,178
Filing Date: August 2, 2016
Intellectual Property Filed
WU Ref.: 2021 (Patent filing information ) T-019682
Invention Disclosure: “HOXB13 lysine 13 acetylation monoclonal antibodies to diagnose high-risk clinically significant prostate cancer”
Financial Disclosures
CONSULTING RELATIONSHIPS AND BOARD MEMBERSHIPS: Technogenesys: Co-Founder and Chief Scientific Officer